Citigroup
GANX icon

Citigroup’s Gain Therapeutics GANX Stock Holding History

Citigroup’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$2 – 5929
2026
Q1 		$2 Buy
+1
New +$2 ﹤0.01% 5830
2025
Q1 		– Sell
-2,000
Closed -$4.32K – 5714
2024
Q4 		$4.32K Buy
+2,000
New +$4.01K ﹤0.01% 5477
2024
Q2 		– Sell
-684
Closed -$2.58K – 5649
2024
Q1 		$2.58K Buy
+684
New +$2.84K ﹤0.01% 5369

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citigroup's GANX Position: Q2 2026 in Review

Citigroup sold out of Gain Therapeutics (GANX) in Q2 2026, closing a stake of 1 share — an estimated $2 sold.

Citigroup first reported a position in GANX in Q1 2024 and held it in 3 quarters. The position peaked at $4.32K in Q4 2024. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Citigroup reported no remaining Gain Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Gain Therapeutics share in Q2 2026, an estimated $2.
  • Citigroup first reported a position in Gain Therapeutics in Q1 2024 and held it in 3 quarters.
  • Citigroup's Gain Therapeutics position peaked at $4.32K in Q4 2024.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.